Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | STK39 | Q9UEW8 | 1/20 | 0.35 |
| ▸ | RHEB | Q15382 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16632982 | 0.87 | TTR (0.48) | ARNCEH1KMT2ACCR2SLC6A4 | |
| SCHEMBL16632358 | 0.86 | NCEH1 (0.38) | ARNCEH1CCR2SLC6A4SLC6A3 | |
| SCHEMBL16632380 | 0.85 | AR (0.40) | ARCA1CA2NCEH1CYP11B1 | |
| SCHEMBL16632475 | 0.84 | TTR (0.45) | CA1CA2POLBGAAKMT2A | |
| SCHEMBL16632419 | 0.84 | AR (0.52) | ARCA1CA2NCEH1SLC6A4 | |
| SCHEMBL16632510 | 0.83 | CA1 (0.46) | ARCA1CA2NCEH1POLB | |
| SCHEMBL16632470 | 0.78 | TTR (0.47) | ARCA1CA2NCEH1KMT2A | |
| SCHEMBL16632713 | 0.77 | TTR (0.46) | ARNCEH1KMT2ASLC6A4SLC6A3 | |
| SCHEMBL16632677 | 0.77 | CA2 (0.42) | ARCA1CA2NCEH1KMT2A | |
| SCHEMBL16632458 | 0.76 | SLC6A4 (0.60) | ARNCEH1SLC6A4SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382245-B2 | Compounds and methods for treating HIV infections | YALE UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | POLM, POLRMT, DHFR | AR 3070/4885CA1 4637/4885CA2 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.